Faron Pharmaceuticals Ltd: Holding(s) in Company
TURKU, FI / ACCESS Newswire / August 8, 2025 /Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)
Faron Pharmaceuticals Ltd | Company announcement | August 08, 2025 at 17:00:00 EEST
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | Faron Pharmaceuticals Ltd | |||||
1b. Please indicate if the issuer is a non-UK issuer(please mark with an "X" if appropriate) | ||||||
Non-UK issuer | X | |||||
2. Reason for the notification(please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | ||||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | X | |||||
Other (please specify) iii: Change due theAdvanced Amortisation of the First Tranche Bonds | X | |||||
3. Details of person subject to the notification obligationiv | ||||||
Name | Timo Syrjälä | |||||
City and country of registered office (if applicable) | Monaco | |||||
4. Full name of shareholder(s) (if different from 3.) v | ||||||
Name | ||||||
City and country of registered office (if applicable) | ||||||
5. Date on which the threshold was crossed or reachedvi: | 07/08/2025 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 08/02/2025 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer (8.A + 8.B) vii | |||
Resulting situation on the date on which threshold was crossed or reached | 14.997% | 14.997% | 16,918,396 | |||
Position of previous notification (if | 15.15% | 15.15% | 16,903,396 |
| |||||||||
A: Voting rights attached to shares | |||||||||
Class/type of | Number of voting rightsix | % of voting rights | |||||||
Direct | Indirect | Direct | Indirect | ||||||
FI4000153309 | 5,330,368 | 11,588,028 | 4.73% | 10.27% | |||||
SUBTOTAL 8. A | 16,918,396 | 14.997 % | |||||||
B 1: Financial Instruments according to DTR5.3.1R (1) (a) | |||||||||
Type of financial instrument | Expiration | Exercise/ | Number of voting rights that may be acquired if the instrument is | % of voting rights | |||||
SUBTOTAL 8. B 1 | |||||||||
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) | |||||||||
Type of financial instrument | Expiration | Exercise/ | Physical or cash | Number of voting rights | % of voting rights | ||||
SUBTOTAL 8.B.2 | |||||||||
9. Information in relation to the person subject to the notification obligation(please mark the | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii | ||||
Full chain of controlled undertakings through which the voting rights and/or the | X | |||
Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
Timo Syrjälä (Direct) | 4.73% | 4.73% | ||
Acme Investments SPF Sarl (Indirect) | 10.27% | 10.27% | ||
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder | ||||
The number and % of voting rights held | ||||
The date until which the voting rights will be held | ||||
11. Additional informationxvi | ||||
Faron Advanced Amortisation of the First Tranche Bonds 07.08.2025 |
Place of completion | Monaco |
Date of completion | 08/08/2025 |
SOURCE: Faron Pharmaceuticals
View the original press release on ACCESS Newswire
© 2025 ACCESS Newswire. All Rights Reserved.
BREAKING NEWS: Herbal Works Inc. Announces New Pet Division of the Herbal Works Product Line
Building Self-Control Through Mindful Practices

